EPIC Health Systems home
Reach Us
BMC Health Services Research · October 2022

Cost-utility analysis of caspofungin vs fluconazole for invasive candidiasis in Ethiopia

Gebremedhin Beedemariam Gebretekle, Atalay Mulu Fentie, Girma Tekle Gebremariam, Eskinder Eshetu Ali, Daniel Asfaw Erku, Tinsae Alemayehu, Workeabeba Abebe, Beate Sander

A Markov-model economic evaluation, from the Ethiopian health-system perspective, comparing caspofungin- versus fluconazole-initiated antifungal therapy for invasive candidiasis and candidaemia. Caspofungin improved outcomes but was not cost-effective as first line; fluconazole first, with caspofungin reserved for second line, was the cost-effective pathway.

EPIC authors:

Cite this

Gebretekle, G. B., Fentie, A. M., Gebremariam, G. T., Ali, E. E., Erku, D. A., Alemayehu, T., Abebe, W., & Sander, B. (2022). Cost-utility analysis of caspofungin vs fluconazole for invasive candidiasis in Ethiopia. BMC Health Services Research. https://doi.org/10.1186/s12913-022-08662-3

More in Health financing & governance
All publications
Partners & collaborators

Who we work with